Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Georgia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 41 | 2,404 | 43% |
| 2020 | 30 | 1,853 | 46% |
| 2021 | 30 |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in Georgia; 19 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 495 | 93,642−4.3%/yr | −4.3%/yr | 113.01.0× | 53% | 102,100 in 2030+1.5%/yr |
| Bronchoscopy & lung nodule |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Georgia · Every state · Compare with Florida
| 2024 |
| 1,940 |
| 59% |
| 2025 est. | ≈ 2,120 | – |
| 2026 est. | ≈ 2,170 | – |
| 1,948 |
| 51% |
| 2022 | 28 | 1,850 | 54% |
| 2023 | 32 | 2,046 | 57% |
| 2024 | 39 | 1,940 | 59% |
| 2025 from claims | – | 2,122 1,948–2,245 | 60% |
| 2026 forecast | – | 2,169 1,908–2,502 | 60% |
| 2027 forecast | – | 2,209 1,889–2,633 | 61% |
| 2028 forecast | – | 2,251 1,878–2,756 | 62% |
| 2029 forecast | – | 2,292 1,872–2,875 | 62% |
| 2030 forecast | – | 2,334 1,870–2,991 | 63% |
In 2025, 44% inpatient hospital, 56% hospital outpatient.
| −0.2%/yr |
| 3.6 |
| 6% |
| 10,200 in 2030+5.1%/yr |
| North Carolina | 52 | 3,646−1.8%/yr | −1.8%/yr | 3.8 | 5% | 3,960 in 2030+1.4%/yr |
| Virginia | 48 | 3,175+1.2%/yr | +1.2%/yr | 3.1 | 0% | 3,690 in 2030+2.6%/yr |
| Maryland | 36 | 2,499+2.9%/yr | +2.9%/yr | 2.9 | 1% | 3,770 in 2030+7.1%/yr |
| South Carolina | 38 | 2,414+3.9%/yr | +3.9%/yr | 3.6 | 1% | 3,510 in 2030+6.4%/yr |
| Tennessee | 45 | 1,981−2.7%/yr | −2.7%/yr | 2.9 | 7% | 2,310 in 2030+2.6%/yr |
| Kentucky | 24 | 1,609−3%/yr | −3%/yr | 3.6 | 2% | 1,660 in 2030+0.5%/yr |
| Louisiana | 24 | 1,549−3.9%/yr | −3.9%/yr | 3.9 | 11% | 1,580 in 2030+0.3%/yr |
| Alabama | 21 | 1,343−4.1%/yr | −4.1%/yr | 3.1 | 11% | 1,700 in 2030+4%/yr |
| West Virginia | 12 | 913−4.3%/yr | −4.3%/yr | 4.5 | 0% | 1,000 in 2030+1.5%/yr |
| Oklahoma | 13 | 913−5.4%/yr | −5.4%/yr | 1.9 | 0% | 1,080 in 2030+2.9%/yr |
| Arkansas | 12 | 721−1.7%/yr | −1.7%/yr | 1.9 | 0% | 990 in 2030+5.4%/yr |
| District of Columbia | 6 | 706−0.3%/yr | −0.3%/yr | 11.4 | 0% | 760 in 2030+1.2%/yr |
| Mississippi | 11 | 634−4%/yr | −4%/yr | 1.7 | 5% | 710 in 2030+1.9%/yr |
| Delaware | 10 | 417−1.5%/yr | −1.5%/yr | 2.5 | 0% | 470 in 2030+2%/yr |
| 43 |
| 2,875+5.7%/yr |
| +5.7%/yr |
| 3.41.0× |
| 0% |
| 5,590 in 2030+12%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Vibrant Gastro leads with 42% of company spending on these surgeons in 2025, −30 pts on 2024.
In 2025, 17 companies reported engagement with Georgia’s surgeons worth $60K in consulting, speaking, meals and travel tied to these products, about $1,549 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.